These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22920397)

  • 1. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
    Soverini S; Martinelli G; Rosti G; Iacobucci I; Baccarani M
    Pharmacogenomics; 2012 Aug; 13(11):1271-84. PubMed ID: 22920397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
    Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
    Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
    Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
    Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
    Mauro MJ
    Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
    [No Abstract]   [Full Text] [Related]  

  • 8. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C
    Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 10. Loss of response to imatinib: mechanisms and management.
    Shah NP
    Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
    Soverini S; Martinelli G; Amabile M; Poerio A; Bianchini M; Rosti G; Pane F; Saglio G; Baccarani M; ;
    Clin Chem; 2004 Jul; 50(7):1205-13. PubMed ID: 15107311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.
    Bumbea H; Vladareanu AM; Voican I; Cisleanu D; Barsan L; Onisai M
    J Med Life; 2010; 3(2):162-6. PubMed ID: 20968202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
    Nimmanapalli R; Bhalla K
    Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Mauro MJ
    Cancer Control; 2009 Apr; 16(2):108-21. PubMed ID: 19337197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.